next agonist
What a safe tanning drug would actually have to be
This is an analysis piece, not a report of something that exists. No approved, general-public tanning-and-photoprotection drug is on the market or announced. But the requirements for one are now specific enough to write down — and writing them down is its own kind of progress.
One note, because this site is careful about it: nothing here describes how to obtain or use any compound. This is about what would have to be built, not how to source what shouldn’t be.
The Melanotan story reads as a series of near-misses only because we can now name what “hitting the target” would actually require. Four things. Three of them look tractable. The fourth is the wall.
One — selectivity
The central lesson of Melanotan II is that hitting the entire melanocortin family makes a drug impossible for casual use: the appetite suppression, the arousal, the central effects are the price of admission for the tan (one hormone, five receptors). A consumer photoprotective would have to be MC1R-selective — the pigment receptor, and nothing else.
This is the most tractable of the four. Receptor-selective medicinal chemistry has advanced enormously since the 1980s, and selective melanocortin ligands are an active area of drug design. The shotgun was a product of its era, not a law of nature.
Two — a safety profile built for healthy people
A drug for sick people can carry risks a drug for well people cannot. A photoprotective taken by millions of healthy adults would face the strictest safety bar in medicine — and it would have to retire, at scale, the specific question the gray-market era raised: does long-term melanocortin stimulation promote melanoma, or does it merely darken the moles we rely on to catch it (the mole problem)? A general-use drug has to answer that question, not inherit it.
Three — a delivery format people would actually use
The approved cousin, afamelanotide, ships as an implant a clinician places under the skin (the middle-ground agonist already exists). That’s entirely reasonable for a rare disease and a complete non-starter for the general public. A consumer version would need something people tolerate as routine: a self-administered injection on the model of the GLP-1 pens, or — better — a topical or an oral. The delivery problem is engineering, and engineering of a kind the industry is now very good at.
Four — proof that it protects, not just tans
This is the hard one, and it gets its own article (the prevention-trial problem). A tan is only modest protection; proving that a drug-induced tan meaningfully lowers skin-cancer rates in a population is a mountain of trial design, time, and money. It is categorically harder than everything above it on this list.
Where that leaves the ledger
Three of the four requirements are chemistry-and-engineering problems that look solvable, and are partly solved already. The fourth is an evidence-and-economics problem that no one has yet chosen to fund for the general population. That’s the honest shape of it: the spec is written, and most of it is buildable. The check to run the decisive trial is what hasn’t been signed — which is a very different, and more hopeful, kind of obstacle than “it can’t be done.” Labeled hope, as everything in this pillar is.